NORAD and triple-negative breast carcinoma: Bernardes de Jesus and colleagues uncover how NORAD downregulation sensitizes triple-negative breast cancer cells to chemotherapy, through an impaired DNA damage response, highlighting how NORAD may represent an unexploited therapeutic target for breast cancer.